David Chung MD PhD

Oncology•New York, NY

Hematologic Oncology

Director, Clinical Research and System Chief, Multiple Myeloma, Northwell Health Cancer Institute

Join to View Full Profile

530 East 74th StreetNew York, NY 10021

Summary

David Chung, MD, based in New York, is a specialist in Oncology with a subspecialty in Hematologic Oncology. His education includes a residency in Internal Medicine at UCLA David Geffen School of Medicine/UCLA Medical Center from 2001-2004, a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center from 2004-2008, and a medical degree from Georgetown University School of Medicine (Class of 2001). Dr. Chung has expertise in immunotherapy, hematologic oncology, bone marrow transplantation, plasma cell myeloma, and multiple myeloma. He has published extensively in the field and has been involved in multiple clinical trials. Dr. Chung's notable contributions have been recognized with numerous awards, including the Myeloma Crowd Research Award and the Clinical Investigation Award from Experimental Therapeutics Center, MSKCC, among others.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2001 - 2004
Georgetown University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2020 - Present
NY State Medical License 2004 - 2027
CT State Medical License 2023 - 2026
CA State Medical License 2002 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Myeloma Crowd Research Award Myeloma Crowd Foundation, 2018
Clinical Investigation Award Experimental Therapeutics Center, MSKCC, 2014
Translational New Investigator Award Department of Defense, 2011
Young Investigator Award American Society of Clinical Oncology, 2006
Mortimer J. Lacher Fellowship The Lymphoma Foundation, 2006
Join now to see all

Clinical Trials

CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2014 Jan 31
Completed
Phase 1
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant Start of enrollment: 2016 Dec 13
Terminated
Phase 1
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Start of enrollment: 2016 Jul 01
Completed
Phase 2

Publications & Presentations

PubMed

1 citations
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.
Ross S Firestone, Anish K Simhal, Devin McAvoy, Eric M Jurgens, Juan-Jose Garcés
Clinical Cancer Research. 2025-11-03
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.
Malin Hultcrantz, Andriy Derkach, Hani Hassoun, Neha Korde, Kylee Maclachlan
Blood Neoplasia. 2025-08-01
1 citations
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.
Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian
Blood Cancer Journal. 2025-07-02

Abstracts/Posters

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma...
2021 ASH Annual Meeting - 12/13/2021
Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenanc...
2020 Transplantation & Cellular Therapy Meetings, Orlando, FL - 2/2020
Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma
17th International Myeloma Workshop, Boston, MA - 10/2019
Antitumor vaccination for multiple myeloma
Fifth Annual Immunotherapy in Myeloma Scientific Workshop, Denver, CO - 5/2019
Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all